FDA Commissioner Scott Gottlieb resigns

FDA Commissioner Scott Gottlieb, MD, is resigning. Gottlieb has manned the agency since May 2017 and will leave his position in about a month.

A number of Trump appointees, particularly White House staffers, have left their positions prematurely. Compared to the administration’s stance on deregulation, Gottlieb has been “adept in issuing new rules,” the Wall Street Journal stated. The agency has taken a harder stance on supplements and is looking into the marketing practices of e-cigarettes.

“All of us at HHS are proud of the remarkable work Commissioner Gottlieb has done at the FDA,” HHS Secretary Alex Azar said in a statement March 5. “He has been an exemplary public health leader, aggressive advocate for American patients and passionate promoter of innovation. I will personally miss working with Scott on the important goals we share, and I know that is true for so many other members of the HHS family.”

Under Gottlieb’s lead, the agency has also focused on streamlining the approval of new, innovative medical devices and drugs that aim to improve healthcare outcomes and lower costs.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

A string of executive orders from the White House created serious concerns among radiologists and other healthcare providers throughout the United States. The American College of Radiology issued a statement to help guide its members through the chaos. 

Bridgefield Capital, founded in 2015, has previously invested in such popular brands as Cirque Du Soleil, Del Monte and Quiksilver. This transaction is expected to be completed in the second half of 2025. 

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it.